Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia.
B cells
Chronic lymphocytic leukemia
Dimethyl Itaconate
Inflammation
Toll like receptors
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
30
06
2023
received:
04
02
2023
accepted:
07
08
2023
medline:
23
10
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
Chronic lymphocytic leukemia (CLL) co-evolves with its own microenvironment where inflammatory stimuli including toll-like receptors (TLR) signaling can protect CLL cells from spontaneous and drug-induced apoptosis by upregulating IκBζ, an atypical co-transcription factor. To dissect IκBζ-centered signaling pathways, we performed a gene expression profile of primary leukemic cells expressing either high or low levels of IκBζ after stimulation, highlighting that IκBζ is not only an inflammatory gene but it may control metabolic rewiring of malignant cells thus pointing to a novel potential opportunity for therapy. We exploited the capacity of the dimethyl itaconate (DI), an anti-inflammatory electrophilic synthetic derivative of the metabolite Itaconate, to target IκBζ. CLL cells, murine leukemic splenocytes, and leukocytes from healthy donors were treated in vitro with DI that abolished metabolic activation and reduced cell viability of leukemic cells only, even in the presence of robust TLR prestimulation. RNA sequencing highlighted that in addition to the expected electrophilic stress signature observed after DI treatment, novel pathways emerged including the downregulation of distinct MHC class II complex genes. In conclusion, DI not only abrogated the proinflammatory effects of TLR stimulation but also targeted a specific metabolic vulnerability in CLL cells.
Identifiants
pubmed: 37561992
doi: 10.1002/eji.202350418
doi:
Substances chimiques
dimethyl itaconate
11JIB0YI93
Toll-Like Receptors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2350418Informations de copyright
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Bosch, F. and Dalla-Favera, R., Chronic lymphocytic leukaemia: from genetics to treatment. Nat. Rev. Clin. Oncol. 2019. 16: 684-701.
Dadashian, E. L., McAuley, E. M., Liu, D., Shaffer, A. L., Young, R. M., Iyer, J. R., Kruhlak, M. J. et al., TLR signaling is activated in lymph node-resident CLL cells and is only partially inhibited by ibrutinib. Cancer Res. 2019. 79: 360-371.
Bruch, P.-M., Giles, H. A., Kolb, C., Herbst, S. A., Becirovic, T., Roider, T., Lu, J. et al., Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. Mol. Syst. Biol. 2022. 18: e10855.
Longo, P. G., Laurenti, L., Gobessi, S., Petlickovski, A., Pelosi, M., Chiusolo, P., Sica, S. et al., The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007. 21: 110-120.
Kennedy, E., Coulter, E., Halliwell, E., Profitos-Peleja, N., Walsby, E., Clark, B., Phillips, E. H. et al., TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood 2021, 137: 3064-3078.
Tarnani, M., Laurenti, L., Longo, P. G., Piccirillo, N., Gobessi, S., Mannocci, A., Marietti, S. et al., The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia. Leuk. Res. 2010. 34: 1189-1194.
Dampmann, M., Görgens, A., Möllmann, M., Murke, F., Dührsen, U., Giebel, B. and Dürig, J., CpG stimulation of chronic lymphocytic leukemia cells induces a polarized cell shape and promotes migration in vitro and in vivo. PLoS One 2020. 15: e0228674.
Efremov, D. G., Bomben, R., Gobessi, S. and Gattei, V., TLR9 signaling defines distinct prognostic subsets in CLL. Front. Biosci. 2013. 18: 371.
Bomben, R., Gobessi, S., Dal Bo, M., Volinia, S., Marconi, D., Tissino, E., Benedetti, D. et al., The miR-1792 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia 2012. 26: 1584-1593.
Fonte, E., Apollonio, B., Scarfò, L., Ranghetti, P., Fazi, C., Ghia, P., Caligaris-Cappio, F. et al., In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of toll-like receptors. Clin. Cancer Res. 2013. 19: 367-379.
Fonte, E., Vilia, M. G., Reverberi, D., Sana, I., Scarfò, L., Ranghetti, P., Orfanelli, U. et al., Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells. Haematologica 2017. 102: 1901-1912.
Willems, M., Dubois, N., Musumeci, L., Bours, V. and Robe, P. A., IκBζ: an emerging player in cancer. Onco. Targets Ther. 2016. 4: 66310-66322.
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C. et al., Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 2019. 10: 1523.
Zhou, G. and Xia, J., OmicsNet: A web-based tool for creation and visual analysis of biological networks in 3D space. Nucleic Acids Res. 2018. 46: W514-W522.
Galicia-Vázquez, G. and Aloyz, R., Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? Crit. Rev. Oncol. Hematol. 2019. 134: 65-70.
Bambouskova, M., Gorvel, L., Lampropoulou, V., Sergushichev, A., Loginicheva, E., Johnson, K., Korenfeld, D. et al., Electrophilic properties of itaconate and derivatives regulate the IκBζ-ATF3 inflammatory axis. Nature 2018. 556: 501-504.
Mills, E. L., Ryan, D. G., Prag, H. A., Dikovskaya, D., Menon, D., Zaslona, Z., Jedrychowski, M. P. et al., Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 2018. 556: 113-117.
O'Neill, L. and Artyomov, M. N., Itaconate: the poster child of metabolic reprogramming in macrophage function. Nat. Rev. Immunol. 2019. 19: 273-281.
Primo, D., Scarfò, L., Xochelli, A., Mattsson, M., Ranghetti, P., Espinosa, A. B., Robles, A. et al., A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. Onco. Targets Ther. 2018. 9: 26019-26031.
Bichi, R., Shinton, S. A., Martin, E. S., Koval, A., Calin, G. A., Cesari, R., Russo, G. et al., Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci. USA 2002. 99: 6955-6960.
Wu, R. P., Hayashi, T., Cottam, H. B., Jin, G., Yao, S., Wu, C. C. N., Rosenbach, M. D. et al., Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2010. 107: 7479-7484.
Nakkala, J. R., Yao, Y., Zhai, Z., Duan, Y., Zhang, D., Mao, Z., Lu, L. et al., Dimethyl itaconate-loaded nanofibers rewrite macrophage polarization, reduce inflammation, and enhance repair of myocardic infarction. Small 2021. 17: 2006992.
Shan, Q., Li, X., Zheng, M., Lin, X., Lu, G., Su, D. and Lu, X., Protective effects of dimethyl itaconate in mice acute cardiotoxicity induced by doxorubicin. Biochem. Biophys. Res. Commun. 2019. 517: 538-544.
Kuo, P.-C., Weng, W.-T., Scofield, B. A., Paraiso, H. C., Brown, D. A., Wang, P.-Y., Yu, I.-C. et al., Dimethyl itaconate, an itaconate derivative, exhibits immunomodulatory effects on neuroinflammation in experimental autoimmune encephalomyelitis. J. Neuroinflammation. 2020. 17: 138.
Gu, L., Lin, J., Wang, Q., Li, C., Peng, X., Fan, Y., Lu, C. et al., Dimethyl itaconate protects against fungal keratitis by activating the Nrf2/HO-1 signaling pathway. Immunol. Cell Biol. 2020. 98: 229-241.
Gautam, A. K., Kumar, P., Raj, R., Kumar, D., Bhattacharya, B., Rajinikanth, P. S., Chidambaram, K. et al., Preclinical evaluation of dimethyl itaconate against hepatocellular carcinoma via activation of the e/iNOS-mediated NF-κB-dependent apoptotic pathway. Front. Pharmacol. 2021. 12: 823285.
Wang, Q., Li, X. L., Mei, Y., Ye, J.-C., Fan, W., Cheng, G.-H., Zeng, M.-S. et al., The anti-inflammatory drug dimethyl itaconate protects against colitis-associated colorectal cancer. J. Mol. Med. 2020. 98: 1457-1466.
Hayashi, K., Nakazato, Y., Ouchi, M., Fujita, T., Endou, H. and Chida, M., Antitumor effect of dimethyl itaconate on thymic carcinoma by targeting LDHA-mTOR axis. Life Sci. 2021. 282: 119847.
Kimura, A., Kitajima, M., Nishida, K., Serada, S., Fujimoto, M., Naka, T., Fujii-Kuriyama, Y. et al., NQO1 inhibits the TLR-dependent production of selective cytokines by promoting IκB-ζ degradation. J. Exp. Med. 2018. 215: 2197-2209.
Sanchez-Lopez, E., Ghia, E. M., Antonucci, L., Sharma, N., Rassenti, L. Z., Xu, J., Sun, B. et al., NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Cell Death Differ. 2020. 27: 2206-2216.
Pillai, R., Hayashi, M., Zavitsanou, A.-M. and Papagiannakopoulos, T., NRF2: KEAPing tumors protected. Cancer Discov. 2022. 12: 625-643.
Minton, A. R., Smith, L. D., Bryant, D. J., Strefford, J. C., Forconi, F., Stevenson, F. K., Tumbarello, D. A. et al., B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells. Explor. Target Antitumor Ther. 2022. 3: 37-49.
Grioni, M., Brevi, A., Cattaneo, E., Rovida, A., Bordini, J., Bertilaccio, M. T. S., Ponzoni, M. et al., CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism. Blood Adv. 2021. 5: 2817-2828.
Bagnara, D., Kaufman, M. S., Calissano, C., Marsilio, S., Patten, P. E. M., Simone, R., Chum, P. et al., A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011. 117: 5463-5472.
Os, A., Bürgler, S., Ribes, A. P., Funderud, A., Wang, D., Thompson, K. M., Tjønnfjord, G. E. et al., Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep. 2013. 4: 566-577.
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P. et al., iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018. 131: 2745-2760.
Edgar, R., Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002. 30: 207-210.
Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J. R., Maciejewski, A. and Wishart, D. S., Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 2016. 44: W147-W153.
Excoffier, L., Gouy, A., Daub, J. T., Shannon, P., Markiel, A., Ozier, O., Baliga, N. S. et al., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Nucleic. Acids Res. 2017. 45: e149.
Heberle, H., Meirelles, V. G., da Silva, F. R., Telles, G. P. and Minghim, R., InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinf. 2015. 16: 169.
Xu, J., Gong, B., Wu, L., Thakkar, S., Hong, H. and Tong, W., Comprehensive assessments of RNA-seq by the SEQC consortium: FDA-led efforts advance precision medicine. Pharmaceutics 2016. 8: 8.